TY - CHAP M1 - Book, Section TI - Bronchogenic Carcinoma A1 - Wang, Sunny A2 - Papadakis, Maxine A. A2 - McPhee, Stephen J. A2 - Rabow, Michael W. A2 - McQuaid, Kenneth R. Y1 - 2022 N1 - T2 - Current Medical Diagnosis & Treatment 2022 AB - Key Clinical Updates in Bronchogenic CarcinomaROS1-rearranged lung cancers respond to crizotinib (ALK, cMET, and ROS1 tyrosine kinase inhibitor) and entrectinib (multikinase inhibitor, including ROS-1) with response rates over 70%.For patients whose NSCLC reveals NTRK 1/2/3 gene fusion, treatment with larotrectinib (TRKA/B/C inhibitor) or entrectinib (multikinase inhibitor, including TRKA/B/C) is recommended.Selpercatinib and pralsetinib (RET inhibitors) are recommended first-line treatments for RET fusion-positive NSCLC. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accessmedicine.mhmedical.com/content.aspx?aid=1184389489 ER -